Hello! You're looking at a policy document report on Overton

We track government policy, guidelines, think tank research, working papers and more to help our customers see the impact and influence of their work.

If you fund, produce or manage research or work to influence policy, we'd love to talk. Learn more on our homepage.

Medicare Part B: Expenditures for New Drugs Concentrated among a Few Drugs, and Most Were Costly for Beneficiaries

Flag for USA U.S. Government Accountability Office on November 20th 2015
New Medicare Part B drugs were more likely than new drugs not paid under Part B to be biologics, that is, products derived from living sources; be approved to treat a narrower range of conditions; and to have used a Food and Drug Administration (FDA) program to expedite their development and review.

Topics in this document

Tags you've given this document

You haven't tagged this document yet.

Citations

Cited by 19 other policy documents (16 of them are from other policy sources)
 

All research cited by this document (view in the articles tab)

See details
Medicare: High-Expenditure Part B Drugs
U.S. Government Accountability Office
In 2013, the Medicare program and its beneficiaries spent $20.9 billion on Part B drugs. 4
On page 6
4 For this report, we excluded vaccines for influenza and haemophilus influenzae as well http://www.gao.gov/products/GAO-13-46R
On page 6
See details
A Primer on Medicare: Key Facts About the Medicare Program and the People it Covers
Kaiser Family Foundation
In 2010, nearly 90 percent of Medicare beneficiaries had some form of supplemental coverage. 7
On page 6
7 The Henry J. Kaiser Family Foundation, A Primer on Medicare: Key Facts About the Medicare Program and the People It Covers (Menlo Park, Calif.: Mar. 20, 2015).
On page 6